HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sunitinib and improved diabetes control.

Abstract
There is increasing use of tyrosine kinase inhibitors as targeted therapy for several malignancies. Sunitinib is the first-line treatment for renal cancer and we report a case of a man receiving this medication who also had diabetes. When started on sunitinib he experienced improvement in his diabetes control with reduction in his insulin requirements, which later worsened when sunitinib was reduced or stopped. Several retrospective studies have been performed demonstrating this effect with sunitinib, but to date no prospective studies have been reported. Most tyrosine kinase inhibitors reduce blood glucose levels in diabetics, but some agents, such as nilotinib, may increase them. There is no consensus on the mechanism of action of sunitinib in reducing glucose levels. Several theories have been postulated, such as increased insulin secretion, increased insulin sensitivity, reduced loss of islet cells, the gastrointestinal side effects of sunitinib, or an interaction with other antihyperglycaemic agents.
AuthorsHelen Elizabeth Jane Tyrrell, Thinn Pwint
JournalBMJ case reports (BMJ Case Rep) Vol. 2014 (Dec 24 2014) ISSN: 1757-790X [Electronic] England
PMID25540214 (Publication Type: Case Reports, Journal Article)
Copyright2014 BMJ Publishing Group Ltd.
Chemical References
  • Antineoplastic Agents
  • Blood Glucose
  • Hypoglycemic Agents
  • Indoles
  • Insulin
  • Protein Kinase Inhibitors
  • Pyrroles
  • Sunitinib
Topics
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Blood Glucose (metabolism)
  • Carcinoma, Renal Cell (complications, drug therapy)
  • Diabetes Mellitus, Type 2 (blood, complications, drug therapy)
  • Humans
  • Hypoglycemic Agents (pharmacology, therapeutic use)
  • Indoles (pharmacology, therapeutic use)
  • Insulin (metabolism, therapeutic use)
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors (pharmacology, therapeutic use)
  • Pyrroles (pharmacology, therapeutic use)
  • Sunitinib

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: